Clinical Verification of Peptide Biomarkers for Human Aging

Clinical Verification of Peptide Biomarkers for Human Aging by Standard-Free, Label-Free LC-MS/MS Quanification of Aldehyde-modified Peptides

Aging in human physically refers to a multidimensional process that all the changes were accumulated in a person over time. These aging changes are responsible for the progressive increases in the chance of disease and death associated with them. So far, there are several theories have been developed to understand the aging process, such as cross-linking, which is led by Maillard Reactions. Maillard Reaction is a complex series of reactions between reducing sugar/aldehydes and amino groups on proteins. Under physiological conditions, aldehydes are products of various exogenous and endogenous amines catalyzed by semicarbazide-sensitive amine oxidase (SSAO), a family of heterogeneous enzyme. It was reported that SSAO shows a significant higher catalytic activity, producing more aldehydes in age-related diseases. However, SSAO is not a perfect candidate to be monitored for evaluating aging, because it is widely distributed in tissues, which are not readily accessible sample-sources for clinical applications. In this work, the investigators have found 6 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference among people with different ages.

Study Overview

• Status: Completed
• Conditions: Aging

Detailed Description

The procedure of clinical study was:

1. to get plasma samples from hospital;
2. digestion of plasma protein-mixture by trypsin in lab;
3. run mass spectrometry and monitor the amount of target HSA-peptides.

• Study Type: Observational
• Enrollment (Actual): 253

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 23 years to 72 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

university hospital, plasma samples of physical examination, faculties and staff of a certain university

Description

Inclusion Criteria:

• Cases with different ages

Exclusion Criteria:

• Cases with Diabetes Mellitus and Hepatitis B

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
measurement of the amount of plasma peptides	The investigators have found 6 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference among people with different ages.	two years

Collaborators and Investigators

• Sponsor: Beijing Institute of Technology
• Investigators: Principal Investigator: Yulin Deng, Ph.D, School of Life Science, BIT

Study record dates

Study Major Dates

• Study Start: January 1, 2009
• Primary Completion (Actual): December 1, 2011
• Study Completion (Actual): December 1, 2011

Study Registration Dates

• First Submitted: June 16, 2014
• First Submitted That Met QC Criteria: June 17, 2014
• First Posted (Estimate): June 18, 2014

Study Record Updates

• Last Update Posted (Estimate): June 18, 2014
• Last Update Submitted That Met QC Criteria: June 17, 2014
• Last Verified: June 1, 2014

More Information

Terms related to this study

• Keywords: formaldehyde; Maillard Reaction; cross-linkage; human aging
• Other Study ID Numbers: deng02